Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep 7:5:217-28.
doi: 10.2147/cia.s11473.

Optimal management of sarcopenia

Affiliations
Review

Optimal management of sarcopenia

Louise A Burton et al. Clin Interv Aging. .

Abstract

Sarcopenia is the progressive generalized loss of skeletal muscle mass, strength, and function which occurs as a consequence of aging. With a growing older population, there has been great interest in developing approaches to counteract the effects of sarcopenia, and thereby reduce the age-related decline and disability. This paper reviews (1) the mechanisms of sarcopenia, (2) the diagnosis of sarcopenia, and (3) the potential interventions for sarcopenia. Multiple factors appear to be involved in the development of sarcopenia including the loss of muscle mass and muscle fibers, increased inflammation, altered hormonal levels, poor nutritional status, and altered renin-angiotensin system. The lack of diagnostic criteria to identify patients with sarcopenia hinders potential management options. To date, pharmacological interventions have shown limited efficacy in counteracting the effects of sarcopenia. Recent evidence has shown benefits with angiotensin-converting enzyme inhibitors; however, further randomized controlled trials are required. Resistance training remains the most effective intervention for sarcopenia; however, older people maybe unable or unwilling to embark on strenuous exercise training programs.

Keywords: aged; muscle function; sarcopenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of sarcopenia. Abbreviation: RAAS, renin–angiotensin–aldosterone system.
Figure 2
Figure 2
Effects of ACE inhibitors on skeletal muscle. Abbreviations: ACE, angiotensin-converting enzyme; IL-6, interleukin-6; TNF-α+ tumor necrosis factor-α.

References

    1. Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C. The developmental origins of sarcopenia. J Nutr Health Aging. 2008;12:427–432. - PMC - PubMed
    1. Cesari M, Leeuwenburgh C, Lauretani F, et al. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr. 2006;83:1142–1148. - PMC - PubMed
    1. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. Gerontologist. 2005;45:386. - PMC - PubMed
    1. Szulc P, Munoz F, Marchand F, Chapurlat R, Delmas PD. Rapid loss of appendicular skeletal muscle mass is associated with higher all-cause mortality in older men: the prospective MINOS study. Am J Clin Nutr. 2010;91:1227–1236. - PubMed
    1. Baumgartner RN. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755. Erratum in. Am J Epidemiol. 1999; 149:1161. - PubMed

Substances